No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EDAP EDAP TMS
- 4.770
- +0.150+3.25%
Close Jul 24 16:00 ET
176.99MMarket Cap-8983P/E (TTM)
4.860High4.650Low10.50KVolume4.770Open4.620Pre Close50.31KTurnover0.04%Turnover RatioLossP/E (Static)37.10MShares9.12352wk High3.08P/B140.98MFloat Cap3.60052wk Low--Dividend TTM29.55MShs Float21.640Historical High--Div YieldTTM4.55%Amplitude0.500Historical Low4.790Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading
Lake Street Maintains EDAP TMS(EDAP.US) With Buy Rating, Maintains Target Price $10
Lake Street Keeps Their Buy Rating on EDAP TMS (EDAP)
Piper Sandler Maintains EDAP TMS(EDAP.US) With Buy Rating, Maintains Target Price $9
EDAP TMS Price Target Maintained With a $19.00/Share by HC Wainwright & Co.
Comments
$EDAP TMS(EDAP.US$
EDAP Announces Interim Results from Phase 3 Study Evaluating Robotic HIFU for the Treatment of Deep Infiltrating Endometriosis
EDAP TMS SA (Nasdaq: EDAP) announced interim results from its Phase 3 study evaluating robotic High-Intensity Focused Ultrasound (HIFU) therapy for deep infiltrating endometriosis.
The study, involving 60 patients, aimed to assess acute pelvic pain levels. Key findings include:
1. Robotic HIFU therapy maintained an excellent safety profile, confi...
EDAP Announces Interim Results from Phase 3 Study Evaluating Robotic HIFU for the Treatment of Deep Infiltrating Endometriosis
EDAP TMS SA (Nasdaq: EDAP) announced interim results from its Phase 3 study evaluating robotic High-Intensity Focused Ultrasound (HIFU) therapy for deep infiltrating endometriosis.
The study, involving 60 patients, aimed to assess acute pelvic pain levels. Key findings include:
1. Robotic HIFU therapy maintained an excellent safety profile, confi...
Despite EDAP TMS' promising revenue outlook, it's not boosting its P/S as expected. Shareholders seem skeptical of forecasts, accepting lower selling prices. The steady P/S ratio with the industry hints at anticipated revenue instability, normally a share price booster.
Gapping up
In reaction to earnings/guidance:
• $CalAmp(CAMP.US$ +0.6%
Other news:
• $Cano Health(CANO.US$ +6.1% ( $Humana(HUM.US$ in the running to acquire CANO according to WSJ)
• $Corcept Therapeutics(CORT.US$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial(LPLA.US$ +4.1% (reports monthly activity for August)
• $Dentsply Sirona(XRAY.US$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN(VXX.US$ +2.9% (tr...
In reaction to earnings/guidance:
• $CalAmp(CAMP.US$ +0.6%
Other news:
• $Cano Health(CANO.US$ +6.1% ( $Humana(HUM.US$ in the running to acquire CANO according to WSJ)
• $Corcept Therapeutics(CORT.US$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial(LPLA.US$ +4.1% (reports monthly activity for August)
• $Dentsply Sirona(XRAY.US$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN(VXX.US$ +2.9% (tr...
16
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg